Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

4DMedical (ASX:4DX) has signed a contract with GlaxoSmithKline to supply quantitative lung imaging analytics. The agreement focuses on using 4DMedical’s technology in GSK’s drug development programs. The deal marks further commercial traction for 4DMedical’s proprietary respiratory imaging platform with a major global pharmaceutical company.

4DMedical focuses on respiratory imaging analytics, aiming to give drug developers more granular insight into lung function than traditional scans. This new contract with GlaxoSmithKline places ASX:4DX alongside a large global pharmaceutical group that is active in respiratory drug research. For investors, it adds another real world use case for the company’s technology in clinical and pre clinical settings.

The GSK agreement may influence how you think about 4DMedical’s role in future clinical trials and long term pharma collaborations. While commercial details are not set out here, the partnership highlights how imaging analytics can become more embedded in drug development. This is an area investors often watch for recurring project work and broader industry adoption.

Stay updated on the most important news stories for 4DMedical by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on 4DMedical.ASX:4DX Earnings & Revenue Growth as at Apr 2026

We've flagged 5 risks for 4DMedical. See which could impact your investment.

Investor Checklist

Quick Assessment

⚖️ Price vs Analyst Target: At A$4.76, the share price is roughly 7% above the A$4.47 analyst target. This sits within the 10% band for a fair value signal. ⚖️ Simply Wall St Valuation: Valuation status is marked as unknown. This news should be weighed without relying on a DCF signal. ❌ Recent Momentum: The 30 day return of about 23.6% decline shows weak short term momentum despite the GSK contract headline.

There is only one way to know the right time to buy, sell or hold 4DMedical. Head to Simply Wall St's company report for the latest analysis of 4DMedical's Fair Value.

Key Considerations

📊 The GSK contract supports the commercial case for 4DMedical’s imaging platform in real world drug development settings. 📊 Watch how this deal feeds into future revenue, any follow on projects with large pharma groups, and progress towards improving losses from the current A$172.9m net loss. ⚠️ Shareholders have faced substantial dilution and negative equity, so assess whether contract wins are matched by balance sheet repair over time.

Story Continues

Dig Deeper

For the full picture including more risks and rewards, check out the complete 4DMedical analysis. Alternatively, you can visit the community page for 4DMedical to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 4DX.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments